Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, we further demonstrated that overexpressing PHD2 attenuated inflammation in colon cancer xenograft mice through weakening accumulation of myeloid-derived suppressor cells (MDSCs) and M2-like tumor-associated macrophages (TAMs), as well as secretions of pro-inflammatory cytokines including G-CSF, TNF-α, IL-6, IL-8, IL-1β, and IL-4.
|
31838134 |
2020 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We cocultured colon cancer cell lines (HCT8 or HCT116) with human myeloid leukemia mononuclear cells (THP-1) and found that interleukin-6 and interleukin-1β levels were reduced, and instead, interleukin-10 and Arginase-1 levels were elevated, suggesting that colon cancer cells contributed to M2 polarization of THP-1.
|
31088266 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The resulting HIF-1α/miR-338-5p/IL-6 feedback loop was necessary for drug resistance in colon cancer cell lines.
|
31208913 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of IL-6 trans-signaling therefore offers a new therapeutic window downstream of the EGF-R for the treatment of colon cancer and possibly of other EGF-R related neoplastic diseases.
|
31694340 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that IL6, a proinflammatory cytokine produced in tumor-bearing states, promoted the metastatic colonization of colon cancer cells in association with dysfunctional antitumor immunity.
|
31554639 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterotypic cell-in-cell structures in colon cancer can be regulated by IL-6 and lead to tumor immune escape.
|
31150612 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results showed that IL-6 and integrin ανβ6 are indicators of cancer progression and poor prognosis in patients with colon cancer.
|
30982362 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study examined the influence of paracrine IL-6 signaling on prostate tumor growth using allograft models of mouse prostate cancer (TRAMP-C2), colon cancer (MC38), and melanoma (B16) cell lines in wildtype (WT) and IL-6 knockout (IL-6<sup>-/-</sup> ) mice.
|
30345534 |
2019 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to investigate the effect of macrophage and IL-6 on EMT of colon cancer, we cultured human colon carcinoma cell line SW48 with conditioned medium (CM) from PMA-stimulated monocyte THP-1 cells and tested for IL-6 dependent EMT pathways.
|
30243096 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future studies are required to establish the impact of IL-6 attenuation on survival outcomes in colon cancer.
|
30081854 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Doxorubicin resistance induces IL6 activation in the colon cancer cell line LS180.
|
30344742 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, ELISA assays revealed that both the compounds had higher inhibition properties to various biomarker of colon cancer like IL-6 and COX-2.
|
28425852 |
2018 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IL-6 therapeutics are available for treating colon cancer; however, they are expensive and induce negative side effects.
|
28193578 |
2017 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notch, EGFR/ErbB, IL-6/sIL-6R) help control intestinal injury/regenerative responses and may drive intestinal inflammation and colon cancer initiation and progression.
|
28739265 |
2017 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This analysis identified downregulation of MUC2 and overexpression of IL-6 in colon cancer but not in normal colon tissue, and this expression pattern was correlated with poor survival of colon cancer patients.
|
28725043 |
2017 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CT26 cells, a murine colon cancer cell line, were intradermally injected into wild-type and IL-6-deficient mice.
|
28746799 |
2017 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MSI in colon cancer is linked to a significant increase of immunocompetent cells responsible for the antitumor activity - CD3(+), CD8(+), CD45RO(+), and T-bet(+) lymphocytes and decrease of inhibition factors such as Foxp3, IL-6, IL-17, and TGF-β.
|
27372860 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fermented Herbal Formulas KIOM-MA128 Ameliorate IL-6-Induced Intestinal Barrier Dysfunction in Colon Cancer Cell Line.
|
27980357 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
|
25625841 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-6 is up-regulated in colon cancer tissue at the transcriptional level and is significantly associated with increased risk of relapse.
|
25862884 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.
|
26209639 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined whether RPTS influences the interleukin-6 (IL-6)/Janus kinase (JAK)-signal transducer and activator of transcription-3 (STAT3) apoptosis molecular pathway and looked for colon cancer-related signal transduction pathways or targets inducing apoptosis.
|
26125778 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, cycling hypoxia-specific inflammatory phenotype, characterized by a simultaneous (baculoviral inhibitor of apoptosis repeat-containing 5)(low)/PTGS2(high)/ICAM-1(high)/IL-6(high)/IL-8(high) expression, is associated with a poor prognosis in human colon cancer.
|
25622900 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
15-LOX-1 down-regulation was associated with IL-6 up-regulation in human colon cancer mucosa.
|
25713055 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We treated the colon cancer cell line COGA-1A for 6, 12, and 24h with 1,25-dihydroxyvitamin D3 (1,25-D3), IL-6, TNFα, and with combinations of these compounds.
|
24120915 |
2014 |